Please use this identifier to cite or link to this item:
Title: Memantine for the treatment of dementia. A review on its current and future applications
Author: Folch, Jaume
Busquets Figueras, Oriol
Ettcheto Arriola, Miren
Sánchez-López, E. (Elena)
Verdaguer Cardona, Ester
García López, María Luisa
Olloquequi González, Jordi
Casadesús, Gemma
Beas Zárate, Carlos
Pelegrí i Gabaldà, Carme
Vilaplana i Hortensi, Jordi
Auladell i Costa, M. Carme
Camins Espuny, Antoni
Castro-Torres, Rubén Darío
Keywords: Demència
Malaltia d'Alzheimer
Alzheimer's disease
Issue Date: 13-Mar-2018
Publisher: IOS Press
Abstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brain of extracellular amyloid-β protein (Aβ) and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. The N-Methyl-D-aspartate receptors (NMDAR), ionotropic glutamate receptor, are essential for processes like learning and memory. An excessive activation of NMDARs has been associated with neuronal loss. The discovery of extrasynaptic NMDARs provided a rational and physiological explanation between physiological and excitotoxic actions of glutamate. Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors. It has been demonstrated that MEM preferentially prevents the excessive continuous extrasynaptic NMDAR disease activation and therefore prevents neuronal cell death induced by excitotoxicity without disrupting physiological synaptic activity. The problem is that MEM has shown no clear positive effects in clinical applications while, in preclinical stages, had very promising results. The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as well as in preventing Aβ production, aggregation, or downstream neurotoxic consequences, in part through the blockade of extrasynaptic NMDAR. Thus, the focus of this review is primarily to discuss the efficacy of MEM in preclinical models of AD, consider possible combinations of this drug with others, and then evaluate possible reasons for its lack of efficacy in clinical trials. Finally, applications in other pathologies are also considered.
Note: Reproducció del document publicat a:
It is part of: Journal of Alzheimer's Disease, 2018, vol. 62, p. 1223-1240
Related resource:
ISSN: 1387-2877
Appears in Collections:Articles publicats en revistes (Bioquímica i Fisiologia)
Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
Articles publicats en revistes (Institut de Neurociències (UBNeuro))
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
673955.pdf583.62 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.